Remoxipride

This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0223RD59PE, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide but generally known as remoxipride, which bears US NIH Compound Identifier 54477. European Medicines Agency schedules Remoxipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10275MIG. The term REMOXIPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules remoxipride in its Anatomical Therapeutic Chemical (ATC) Classification. REMOXIPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule remoxipride under HS 29339990 and SITC 51577. As of Q4 2014, REMOXIPRIDE remains the US FDA Preferred Term for this commodity. Remoxipride bears US NLM identifiers UMLS ID C0073047 and NCI Concept Code C73312. SMILES: BRC1C(OC)C(C(=O)NCC2N(CCC2)CC)C(OC)CC1.